Skip to content

PFE · PFIZER INC

32 filings

10-K

PFE 10-K Annual Reports

PFIZER INC - 32 annual reports

Filing record · 2016–202610-K1110-Q328-K146

2025
PFIZER INC Annual Report, Year Ended Dec 31, 2025
Pfizer Inc.'s 2025 10-K filing reveals a company navigating a dynamic landscape, with total revenues experiencing a slight 2% decrease to $62.6 billion, primarily due to a significant decline in COVID-19 product revenues (Comirnaty and Paxlovid). Excluding these products, the company saw a 6% operational revenue increase, driven by strong performance in its Vyndaqel family, Eliquis, Padcev, and oncology portfolio. The company is strategically focused on maximizing value from key transactions, delivering on R&D milestones, investing for post-2028 growth, and scaling AI across its business. Pfizer continues to manage significant patent expirations, anticipating a substantial reduction in revenue from these events between 2026 and 2030, with an expected impact of $1.5 billion in 2026. The company is also actively managing pricing pressures and regulatory changes, including the impact of the IRA and the U.S. government's Most-Favored-Nation initiatives. Significant investments in business development, such as the acquisitions of Seagen and Metsera, underscore Pfizer's commitment to strengthening its pipeline, particularly in oncology and obesity. Despite revenue headwinds from COVID-19 products and upcoming patent cliffs, Pfizer's diversified portfolio, ongoing R&D investments, and strategic business development initiatives position it to address unmet medical needs and drive future growth. Investors will be closely watching the company's ability to execute on its strategic priorities, manage patent expirations, and adapt to the evolving regulatory and pricing environment.
Feb 26, 2026
2024
PFIZER INC Annual Report, Year Ended Dec 31, 2024
Pfizer Inc.'s 2024 Form 10-K highlights a year of revenue growth driven by key products like Paxlovid, the Seagen acquisition, and strong performance from the Vyndaqel family and Eliquis, despite a decline in Comirnaty revenues. Total revenues reached $63.6 billion, a 7% increase year-over-year, with operational growth contributing significantly. The company is strategically focused on improving R&D productivity, expanding margins, achieving commercial excellence, and optimizing capital allocation in 2025. Pfizer continues to navigate a complex regulatory and competitive landscape, including ongoing discussions around drug pricing, patent expirations for key products, and the integration of the Seagen acquisition, which is expected to generate significant synergies. Investors should note the potential impact of upcoming patent expiries between 2026 and 2030 on revenue streams, alongside ongoing efforts to bolster its product pipeline through internal development and strategic business development.
Feb 27, 2025
2023
PFIZER INC Annual Report, Year Ended Dec 31, 2023
Pfizer Inc.'s 2023 Form 10-K filing reveals a significant revenue decline, primarily driven by the substantial decrease in sales of its COVID-19 related products, Comirnaty and Paxlovid. Despite this, the company completed the transformative acquisition of Seagen, significantly bolstering its oncology portfolio with the addition of four in-line medicines and a promising pipeline. Looking ahead, Pfizer is focusing on strategic priorities including achieving oncology leadership, advancing its pipeline for future growth, maximizing the performance of its newer products, and optimizing its cost structure. The company is navigating a dynamic market influenced by increasing pricing pressures, the ongoing patent expirations of key products, and evolving regulatory landscapes globally, including the impact of the Inflation Reduction Act (IRA) in the U.S. Pfizer's robust R&D efforts and strategic business development activities are key to its long-term value creation strategy.
Feb 22, 2024
2022
PFIZER INC Annual Report, Year Ended Dec 31, 2022
Pfizer Inc. reported robust financial performance in 2022, with total revenues reaching $100.3 billion, a significant 23% increase from 2021. This growth was primarily driven by strong sales from Paxlovid and the Comirnaty vaccine, which together accounted for 57% of total revenues. Excluding these COVID-19 related products, operational revenue growth was a more modest 2%, supported by key products like the Prevnar family, Eliquis, and Vyndaqel family, as well as contributions from recent acquisitions. The company's strategic focus remains on advancing its pipeline and capitalizing on growth opportunities through both internal R&D and business development. In 2022, Pfizer completed several strategic acquisitions, including Arena, GBT, and Biohaven, aimed at strengthening its portfolio in immuno-inflammatory diseases and rare diseases. Looking ahead, Pfizer forecasts a significant revenue decline in 2023, primarily due to an expected reduction in COVID-19 product sales, projecting total revenues between $67 billion and $71 billion. The company continues to manage its cost base, optimize R&D operations, and return capital to shareholders through dividends and share repurchases.
Feb 23, 2023
2021
PFIZER INC Annual Report, Year Ended Dec 31, 2021
Pfizer Inc. reported robust financial performance for the fiscal year ended December 31, 2021, driven significantly by the remarkable success of its COVID-19 vaccine, Comirnaty, which accounted for a substantial portion of the company's $81.3 billion in total revenues. This surge in revenue, a 95% increase year-over-year, also saw a significant boost in operational cash flow and diluted earnings per share. The company has strategically focused on its innovative medicines and vaccines portfolio, with recent business development activities including acquisitions and collaborations aimed at strengthening its pipeline in areas like immuno-oncology and inflammatory diseases. Pfizer's operational structure was refined into two segments: Biopharma and Pfizer CentreOne (PC1), with Biopharma being the sole reportable segment. The company continues to prioritize scientific advancement and patient access, while also navigating a complex regulatory and pricing environment across its global operations.
Feb 24, 2022
2020
PFIZER INC Annual Report, Year Ended Dec 31, 2020
Pfizer Inc.'s 2020 10-K report highlights a significant transformation into a focused, innovative biopharmaceutical company following the spin-off of its Upjohn business into Viatris and the formation of the Consumer Healthcare JV. The company experienced revenue growth of 2% year-over-year, reaching $41.9 billion, driven by strong performance in key products like Vyndaqel/Vyndamax and Eliquis, despite an estimated $700 million unfavorable impact from the COVID-19 pandemic. Pfizer's research and development efforts remain robust, with notable progress in its COVID-19 vaccine program in collaboration with BioNTech, which received Emergency Use Authorization (EUA) in multiple countries by the end of 2020. The company's strategic focus on innovation, pipeline advancement, and business development is evident through various collaborations and its commitment to addressing unmet medical needs. While facing typical industry pressures such as pricing and reimbursement challenges and patent expirations, Pfizer's diversified portfolio and strong cash flow position it for continued growth and value creation for shareholders.
Feb 25, 2021
2019
PFIZER INC Annual Report, Year Ended Dec 31, 2019
Pfizer's 2019 Form 10-K reports revenues of $51.8 billion, down 4% from $53.6 billion in 2018, with an operational decline of 1% and a 3% foreign exchange headwind. Reported diluted EPS rose to $2.87 (up 54%) because of an $8.1 billion pre-tax gain on the completion of the GSK Consumer Healthcare joint venture, while Adjusted diluted EPS was $2.95 (up 1%). Operating cash flow fell 20% to $12.6 billion, largely due to upfront payments for Therachon and Akcea and the timing of receipts and payments. The central investor issue is the revenue cliff ahead. Pfizer expects reduced revenues from patent expirations to be significant in 2020, led by Lyrica (U.S. generics began July 2019, with Lyrica revenues down 33% to $3.3 billion) and the Chantix U.S. patent expiry in November 2020. Management guides 2020 revenues to $48.5–50.5 billion for total company and $40.7–42.3 billion for "New Pfizer," which is pro forma for the pending Upjohn combination with Mylan into Viatris. It also flagged a $2.4 billion negative revenue impact from generic and biosimilar competition in 2020, and a plan to cut costs by about $1.0 billion net over 2020–2022 against roughly $1.4 billion in restructuring costs. Portfolio and balance sheet changes were significant. Pfizer acquired Array BioPharma for about $11.2 billion, took a 32% stake in the GSK Consumer Healthcare JV, and agreed to combine Upjohn with Mylan (Pfizer shareholders to own 57% of Viatris), with closing expected mid-2020. Total debt rose to about $52 billion, and short-term borrowings increased to $16.2 billion, so working capital turned negative at $(4.5) billion. Pfizer repurchased $8.9 billion of stock and paid $8.0 billion in dividends, and it expects an approximately $600 million repatriation tax installment in April 2020 as part of a roughly $15 billion TCJA liability. Key risks include U.S. and China pricing pressure (including China's VBP tender program), FDA manufacturing compliance issues at the McPherson and Meridian sites, and the Upjohn/Mylan deal's execution.
Feb 27, 2020
2018
PFIZER INC Annual Report, Year Ended Dec 31, 2018
Pfizer's 2018 Form 10-K shows a company in transition: revenues rose 2% to $53.6 billion, but reported diluted EPS fell 47% to $1.87, largely because 2017 included a $10.7 billion U.S. tax benefit from the Tax Cuts and Jobs Act and 2018 included about $3.1 billion of intangible asset impairments. On an adjusted (non-GAAP) basis, diluted EPS rose 13% to $3.00. Revenue growth came from key brands such as Ibrance, Eliquis, Xeljanz and Prevnar 13, offset by $2.5 billion of declines from Viagra's loss of exclusivity, Lyrica, Enbrel biosimilar competition and sterile injectables. The most consequential strategic event is the agreement to combine Consumer Healthcare with GSK's consumer business into a joint venture in which Pfizer receives a 32% stake, expected to close in the second half of 2019. Pfizer also reorganized into three businesses (Biopharma, Upjohn and Consumer Healthcare) effective January 2019, and guided 2019 revenue to $52-54 billion and adjusted diluted EPS to $2.82-2.92, reflecting roughly $2.6 billion of expected generic and biosimilar erosion, with Lyrica's U.S. exclusivity ending in mid-2019. Capital return is substantial: $12.2 billion of share repurchases in 2018, with a further roughly $6.8 billion accelerated repurchase in February 2019, and a dividend raised to $0.36 per quarter. Key risks flagged include the FDA's OAI status at the Hospira McPherson, Kansas plant, a possible ACIP vote on Prevnar 13 recommendations for adults 65 and older, pending U.S. drug-pricing rule changes that would alter rebate economics, and ongoing patent and product litigation.
Feb 28, 2019
2017
PFIZER INC Annual Report, Year Ended Dec 31, 2017
Pfizer's 2017 Form 10-K (filed February 22, 2018) reports revenues of $52.5 billion, down 1% from 2016 on an operational decline of less than 1% and a $259 million unfavorable foreign exchange impact. Reported diluted EPS more than doubled to $3.52, but this is inflated by a $10.7 billion net tax benefit from the Tax Cuts and Jobs Act; non-GAAP Adjusted diluted EPS rose 11% to $2.65. Operating cash flow grew 4% to $16.5 billion. The company is organized into two segments: Pfizer Innovative Health (about $31.4 billion, up 8%) and Pfizer Essential Health (about $21.1 billion, down 11%, partly because the HIS infusion business was sold in February 2017). The key investor themes are patent cliffs and growth replenishment. Products with more than $1 billion in revenue made up 46% of 2017 revenue, and management expects a $2.0 billion revenue headwind in 2018 from generic and biosimilar competition, including Lyrica and Viagra in the U.S. Growth is coming from Ibrance, Eliquis, Xeljanz and Xtandi, partly acquired through Medivation (about $14.3 billion) and Anacor. The company also announced a strategic review of its Consumer Healthcare business, with a decision expected in 2018, and it faces ongoing regulatory and litigation issues, including a cGMP warning letter at the McPherson, Kansas facility, which was upgraded to VAI in January 2018, and product shortages at legacy Hospira sites. For 2018, guidance calls for revenue of $53.5 to $55.5 billion and Adjusted diluted EPS of $2.90 to $3.00. The company plans to repatriate most of its international cash and has a $15.2 billion TCJA repatriation tax liability payable over eight years through 2026. Its capital return plans include $5.0 billion in 2018 share repurchases and a dividend increase to $0.34 per quarter.
Feb 22, 2018
2016
PFIZER INC Annual Report, Year Ended Dec 31, 2016
Pfizer's 2016 Form 10-K (filed February 23, 2017) reports revenues of $52.8 billion, up 8% from $48.9 billion in 2015 (an 11% operational increase partly offset by a 3% foreign exchange headwind). The growth was driven largely by the full-year inclusion of Hospira (about $3.1 billion of acquisition-related growth), continued momentum in key brands such as Ibrance, Xeljanz, Eliquis and Chantix, and the Medivation and Anacor acquisitions. Reported earnings were weaker: income from continuing operations before taxes fell 7% to $8.4 billion, and diluted EPS was $1.17 versus $1.11 in 2015, with the increase in net income helped by a lower effective tax rate of 13.4%. Results were pressured by a $1.7 billion write-down of the Hospira Infusion Systems (HIS) net assets, higher restructuring and acquisition-related costs, and asset impairments. On a non-GAAP adjusted basis, diluted EPS was $2.40 versus $2.20. The outlook is a key focus for investors. For 2017, Pfizer guided to revenues of $52.0 to $54.0 billion and adjusted diluted EPS of $2.50 to $2.60. Management cited an expected $2.4 billion revenue hit from generic and biosimilar competition, including Viagra, Pristiq and Lyrica, and a $0.9 billion foreign exchange headwind. The company also launched a new cost-reduction program targeting about $1.2 billion of savings by 2020, and completed the sale of HIS to ICU Medical for up to about $900 million on February 3, 2017. Pfizer is also returning capital, with a $5 billion accelerated share repurchase agreement entered into February 2, 2017 and a dividend increase to $0.32 per quarter. The risk profile is heavily weighted toward loss of exclusivity and pricing pressure. Eight products generating more than $1 billion in direct sales, plus Eliquis alliance revenues, together accounted for 43% of 2016 revenues. Pfizer also flagged U.S. healthcare reform uncertainty (repeal or replacement of the ACA), a February 2017 FDA warning letter for the Hospira McPherson, Kansas facility, and ongoing litigation such as the Lipitor and Effexor matters. Management stated that it is not pursuing a split into two companies at this time, and it continues to operate Innovative Health and Essential Health as two distinct segments.
Feb 23, 2017
2015
PFIZER INC Annual Report, Year Ended Dec 31, 2015
Pfizer's 2015 Form 10-K (filed February 29, 2016) describes a year of heavy portfolio reshaping. Revenues fell 2% to $48.9 billion, as roughly $3.8 billion of unfavorable foreign exchange offset a 6% operational increase. Reported net income attributable to Pfizer declined 24% to $7.0 billion, or $1.11 diluted EPS, driven by Hospira integration costs, purchase accounting charges, a $806 million Venezuela currency loss, and a $784.6 million agreement in principle on Protonix Medicaid rebate claims. Non-GAAP Adjusted diluted EPS was $2.20, down from $2.26. Key growth drivers were Prevnar 13 (up 40% to $6.2 billion), Ibrance (a $723 million launch), Eliquis, Xeljanz and Lyrica in the U.S., while Celebrex (down 69%) and Zyvox (down 35%) suffered generic erosion. The defining strategic events were the September 2015 acquisition of Hospira for about $16.1 billion in cash, which added sterile injectables and biosimilars to the Established Products business, and the November 2015 agreement to combine with Allergan in a stock transaction with an enterprise value of about $160 billion. Under the Allergan terms, Pfizer shareholders would own roughly 56% of the combined company and could elect up to $12 billion in cash, and the combined company would be domiciled in Ireland. Completion is expected in the second half of 2016, subject to U.S. and EU regulatory approval and Allergan's pending divestiture of its generics business to Teva. Pfizer also notes that a termination fee of up to $3.5 billion could apply and that lenders may accelerate credit lines upon the merger. Capital returns remain substantial: $6.2 billion in buybacks and $6.9 billion in dividends in 2015, with the quarterly dividend raised to $0.30 for Q1 2016. Guidance for 2016 calls for reported revenues of $49.0 to $51.0 billion and Adjusted diluted EPS of $2.20 to $2.30, excluding the pending Allergan transaction. Investors should weigh the 2016 loss-of-exclusivity headwind of about $2.3 billion, the $2.3 billion currency headwind, and the Allergan execution risk.
Feb 29, 2016
2014
PFIZER INC Annual Report, Year Ended Dec 31, 2014
Pfizer's 2014 Form 10-K (filed February 27, 2015) shows a year of declining revenue and earnings driven by patent expirations and lost collaboration rights. Revenues fell 4% to $49.6 billion, with an operational decline of 2% and a 2% unfavorable foreign exchange impact. Reported net income attributable to Pfizer was $9.1 billion, down 58% from 2013, which benefited from a $10.3 billion Zoetis gain that year. Diluted EPS was $1.42 on a reported basis versus $2.26 on the company's non-GAAP Adjusted basis, a figure that excludes purchase accounting, acquisition costs and certain significant items. Key pressures included the Enbrel co-promotion expiration in the U.S. and Canada (about $1.4 billion), generic erosion of Lipitor, Celebrex and Lyrica in Europe, and the loss of Spiriva in the U.S. R&D spending rose 26% to $8.4 billion, including a $1.2 billion charge tied to the Merck KGaA collaboration. Management's 2015 guidance calls for reported revenues of $44.5 to $46.5 billion and adjusted diluted EPS of $2.00 to $2.10, while reported EPS is guided to $1.37 to $1.52. The guidance reflects roughly $3.5 billion of revenue loss from product exclusivity losses and $2.8 billion from adverse currency moves. The company also announced a $17 billion cash-and-debt acquisition of Hospira (expected to close in the second half of 2015) and a $5 billion accelerated share repurchase. Pfizer ended the year with $53.6 billion in cash and investments against $36.7 billion in debt, and it increased the quarterly dividend to $0.28. For investors, the central questions are whether the pipeline (including Ibrance, Xeljanz and Eliquis) and the Hospira deal can offset a sizable multi-year loss of exclusivity, and whether the approximately $2.5 billion of expected annual cost savings by 2016 can protect margins. The filing also flags meaningful risks: U.S. pricing and healthcare reform, Medicare SGR legislation, the pending King v. Burwell Supreme Court case, a $400 million securities settlement, Venezuela currency exposure and continuing litigation over Effexor, Lipitor and Neurontin.
Feb 27, 2015
2013
PFIZER INC Annual Report, Year Ended Dec 31, 2013
Pfizer's 2013 Form 10-K (filed February 28, 2014) shows a year defined by patent cliffs and portfolio reshaping. Revenues fell 6% to $51.6 billion, with a 4% operational decline driven mainly by Lipitor erosion (about $1.7 billion) and other losses of exclusivity. Biopharmaceutical revenues were $47.9 billion, and international markets generated 61% of total revenue. Reported net income attributable to Pfizer rose 51% to $22.0 billion, but that figure is inflated by the roughly $10.4 billion pre-tax gain on the Zoetis (Animal Health) disposition, and income from continuing operations rose 26% to $11.4 billion mainly because of a $1.3 billion patent litigation settlement and lower legal charges. Non-GAAP Adjusted income fell 3% to $15.3 billion, and Adjusted diluted EPS rose 6% to $2.22. The company is restructuring its commercial organization into three global businesses effective 2014: the Global Innovative Pharmaceutical business (GIP), the Global Vaccines, Oncology and Consumer Healthcare business (VOC), and the Global Established Pharmaceutical business (GEP). Management expects about $2.9 billion in annual cost savings by the end of 2016. The 2014 guidance projects adjusted revenues of $49.2 to $51.2 billion, reported diluted EPS of $1.57 to $1.72, and adjusted diluted EPS of $2.20 to $2.30. Guidance excludes unannounced business development deals and pending litigation resolutions. Capital returns remain substantial. Pfizer repurchased about $16.3 billion of stock in 2013 and paid $6.6 billion in dividends, with about $5.5 billion remaining on the share-purchase authorization at year-end. The quarterly dividend was raised to $0.26 for Q1 2014. Long-term obligations are heavy, and the company still faces significant exposure to loss of exclusivity for Lipitor, Celebrex, Viagra and others, along with U.S. healthcare reform pricing pressure and European reimbursement cuts.
Feb 28, 2014
2012-A
PFIZER INC Annual Report (Amendment), Year Ended Dec 31, 2012
This filing is Amendment No. 1 (Form 10-K/A) to Pfizer's 2012 Annual Report, filed March 1, 2013. It was filed solely to correct typographical errors in the headers of Exhibit 13 (the 2012 Financial Report) on the cover page and pages 49-120; it does not change any financial results or other information in the original 10-K filed February 28, 2013. The substantive content therefore is the 2012 Financial Report included in the exhibit. For investors, the key figures are: 2012 revenues of $59.0 billion (down 10% from $65.3 billion, driven by roughly $7.7 billion, or 12%, of revenue lost to loss of exclusivity, most notably Lipitor), reported net income attributable to Pfizer of $14.6 billion (EPS of $1.94 diluted, boosted by a roughly $4.8 billion after-tax gain on the sale of the Nutrition business to Nestlé for $11.85 billion), and non-GAAP Adjusted diluted EPS of $2.19 (down from $2.27). Management guided 2013 to revenues of $56.2-58.2 billion, reported diluted EPS of $1.50-1.65, and Adjusted diluted EPS of $2.20-2.30, and said it would update guidance in April 2013 to reflect the February 2013 IPO of about 19.8% of Zoetis, the animal health unit. Pfizer retains roughly 80% of Zoetis and has said it may later distribute the remaining stake tax-free. Cash from operations fell to $17.1 billion from $20.2 billion. The company repurchased about $8.2 billion of stock in 2012 and holds a new $10 billion buyback authorization, with roughly $11.8 billion of total remaining authorization at year-end. The quarterly dividend was raised to $0.24 for Q1 2013 from $0.22. Investors should also note the large 2013-2016 pipeline of patent expirations (Aricept, Spiriva, Enbrel's U.S. and Canada co-promotion ending October 2013, Rebif, Detrol LA and others) and significant legal charges in 2012 (about $2.2 billion in certain legal matters, including Rapamune, Celebrex/BYU, and Chantix), plus continuing exposure to asbestos (Quigley), hormone-replacement therapy, and Lipitor antitrust litigation. Long-term debt was $31.0 billion, against $81.3 billion of Pfizer shareholders' equity.
Mar 1, 2013
2012
PFIZER INC Annual Report, Year Ended Dec 31, 2012
Pfizer's 2012 Form 10-K (filed February 28, 2013) shows a company in transition: revenues fell 10% to $59.0 billion, driven by the loss of exclusivity of Lipitor (which fell 59% to $3.9 billion) and other products, plus $1.5 billion of unfavorable currency effects. Reported net income attributable to Pfizer rose 46% to $14.6 billion, but that was flattered by the $11.85 billion Nutrition sale to Nestlé, which generated a roughly $4.8 billion after-tax gain and $5.1 billion of total discontinued-operations income. Continuing-operations income was $9.5 billion, and Non-GAAP Adjusted income fell 8% to $16.5 billion (Adjusted diluted EPS $2.19 versus $2.27), the measure management uses for compensation. Investors should therefore focus on the underlying erosion of the core business rather than the headline GAAP increase. Management is responding with cost cuts, a smaller R&D budget (R&D fell 13% to $7.9 billion, with 2013 adjusted R&D guided to $6.5–7.0 billion), a reduced workforce (down 12,200 to 91,500), and a 2013 guidance range of $56.2–58.2 billion in revenue and $2.20–2.30 in Adjusted diluted EPS. Capital returns remain significant: $8.2 billion of buybacks in 2012, a new $10 billion authorization, and a dividend increased to $0.24 per quarter. The February 2013 IPO of 19.8% of Zoetis, the animal health unit, brought in about $6.1 billion of cash in total, of which about $2.5 billion is restricted to debt repayment, dividends, or buybacks through mid-2014. Pfizer also faces significant legal exposure, including settled and pending hormone-replacement therapy, Chantix, Quigley asbestos, and off-label promotion matters, and it expects continued pricing pressure in Europe, Japan, and emerging markets, as well as the Affordable Care Act. The balance sheet remains strong, with total assets of $185.8 billion, net financial assets of $9.4 billion (up from a net liability of $2.7 billion), and investment-grade ratings (A1/AA as of 2009). Operating cash flow fell to $17.1 billion from $20.2 billion. The outlook depends on the pipeline and on the 2013–2014 patent expirations for Celebrex, Zyvox, Lyrica, Eliquis, and others, along with Enbrel's U.S. co-promotion expiring in October 2013.
Feb 28, 2013
2011
PFIZER INC Annual Report, Year Ended Dec 31, 2011
Pfizer's 2011 10-K (filed February 28, 2012) reports revenues of $67.4 billion, up 1% year over year, as favorable foreign exchange (about $1.9 billion) and the addition of King Pharmaceuticals (about $1.3 billion) offset a net operational decline of about $2.9 billion, driven mainly by loss of exclusivity on products such as Lipitor, Effexor and Protonix. Reported net income attributable to Pfizer rose 21% to $10.0 billion (diluted EPS $1.27), while Adjusted income, the non-GAAP measure management uses, was $18.2 billion (Adjusted diluted EPS $2.31). Reported results were boosted by the $1.3 billion gain on the Capsugel sale and were reduced by about $4.5 billion of restructuring, litigation and impairment-related charges, so investors should weigh the gap between GAAP and adjusted figures. The main forward-looking issue is the patent cliff. Lipitor, the largest product at about $9.6 billion (roughly 14% of revenue), lost U.S. exclusivity in November 2011, with multi-source generic competition expected from late May 2012 and substantial further losses in Europe. Management guides 2012 revenues of $60.5 to $62.5 billion, reported diluted EPS of $1.37 to $1.52, and Adjusted diluted EPS of $2.20 to $2.30. The company also plans to cut R&D spending, with adjusted R&D expected to fall to roughly $6.5 to $7.0 billion in 2012 from $8.4 billion in 2011, and it is exploring separation or sale of its Animal Health and Nutrition businesses, with decisions expected in 2012. Capital returns remain a key part of the story. The dividend was raised to $0.22 per quarter from $0.20, and the board authorized a new $10 billion repurchase plan in December 2011, with about $5 billion of buybacks expected in 2012. Pfizer ended 2011 with $3.5 billion in cash, $27.0 billion in short-term investments and loans, and $34.9 billion in long-term debt, with net financial liabilities of $2.7 billion and AA/A1 credit ratings. Key risks include U.S. healthcare reform (including the Supreme Court review of the individual mandate), pricing pressure in Europe and emerging markets, hormone-replacement therapy and Quigley asbestos litigation, and the Lipitor and Caduet generic entry.
Feb 28, 2012
2010
PFIZER INC Annual Report, Year Ended Dec 31, 2010
Pfizer's 2010 Form 10-K (filed February 28, 2011) reports full-year 2010 revenues of $67.8 billion, up 36% from $50.0 billion in 2009, driven mainly by a full year of legacy Wyeth products following the October 2009 Wyeth acquisition (~$68 billion). Reported net income attributable to Pfizer fell 4% to $8.3 billion and reported diluted EPS was $1.02 (vs. $1.23), held down by $4.3 billion of other deductions (including $2.1 billion of intangible impairments, a $1.3 billion asbestos charge tied to Quigley, and higher interest expense) and roughly $8.3 billion of purchase accounting charges. Non-GAAP Adjusted diluted EPS rose 10% to $2.23, and the effective tax rate fell to 11.9% on a one-time $1.4 billion IRS audit settlement benefit. Looking ahead, the filing signals a challenging period. Lipitor, the world's best-selling drug at $10.7 billion in 2010, faces U.S. loss of exclusivity in November 2011, and several other major products (Xalatan, Caduet, Aricept 5/10mg, Effexor, Protonix, Vfend tablets) are losing exclusivity. Management guided 2011 revenues of $66.0-68.0 billion and reported diluted EPS of $1.09-1.24 (Adjusted $2.16-2.26), and targeted 2012 Adjusted EPS of $2.25-2.35. It also announced a February 2011 R&D productivity initiative that narrows focus to five therapeutic areas and reduces R&D spending to roughly $8.0-8.5 billion in 2011, with $1.1-1.3 billion of impairment and restructuring charges, including the planned exit from the Sandwich, U.K. site. Capital allocation remains shareholder-friendly. The quarterly dividend rises to $0.20 per share (from $0.18), and the board authorized a new $5 billion buyback, bringing total authorization to $9 billion, with about $5 billion expected to be repurchased in 2011. Pfizer ended 2010 with $28.5 billion in cash and short-term investments and maintained AA (S&P) and A1 (Moody's) long-term ratings. Pending items include the approximately $3.6 billion King Pharmaceuticals acquisition (closing around February 28, 2011, with about 92.5% already tendered), the Ferrosan consumer healthcare purchase, and a review of strategic options for Capsugel.
Feb 28, 2011
2009
PFIZER INC Annual Report, Year Ended Dec 31, 2009
Pfizer's 2009 10-K, filed February 26, 2010, is dominated by the October 15, 2009 acquisition of Wyeth, valued at about $68 billion and funded with roughly $24 billion of senior unsecured notes plus about 1.3 billion treasury shares issued to Wyeth holders. Reported 2009 revenue rose 4% to $50.0 billion, but only about $3.3 billion came from legacy Wyeth products, which were consolidated for under three months. Net income attributable to Pfizer was $8.6 billion, or $1.23 per diluted share, up 7%. Adjusted income, a non-GAAP measure management emphasizes, fell 13% to $14.2 billion, and Adjusted diluted EPS fell to $2.02 from $2.42, reflecting higher share count and interest expense. The balance sheet changed sharply. Total assets rose to $213 billion from $111 billion, with goodwill of $42 billion and intangibles of $68 billion. Net financial position swung from +$18.8 billion of net financial assets to -$8.4 billion of net financial liabilities, and total debt rose to $48.7 billion. Moody's cut Pfizer to A1 and S&P to AA, both still investment grade. Management guides to 2010 revenue of $67–69 billion and Reported EPS of $0.95–$1.10, with Adjusted EPS of $2.10–$2.20, and targets 2012 revenue of $66–68.5 billion. It also plans about $4–5 billion of net cost reductions by 2012. The key risks for investors are the scheduled loss of exclusivity on major products and pending U.S. healthcare reform. Lipitor, which generated $11.4 billion in 2009 (about 25% of Biopharmaceutical revenue), faces generic competition starting in 2010, and Effexor XR generics can launch from July 2010. Pending legislation could mandate Medicare rebates or direct government price negotiation. The filing also discloses substantial legal exposure, including off-label promotion investigations, hormone-replacement therapy suits, and Quigley asbestos matters. Management says these are not expected to be material, but the filing does not quantify a maximum exposure.
Feb 26, 2010
2008
PFIZER INC Annual Report, Year Ended Dec 31, 2008
Pfizer's 2008 10-K reports essentially flat results: revenues of $48.3 billion (vs. $48.4 billion in 2007), net income of $8.1 billion ($1.20 diluted EPS), and Adjusted income of $16.4 billion ($2.42 Adjusted EPS per the filing's framework). Reported profitability was pressured by roughly $8.1 billion in pre-tax certain significant items, including a $2.3 billion charge to resolve a Department of Justice investigation into past off-label Bextra promotion, roughly $900 million in Celebrex/Bextra and NSAID litigation charges, $4.2 billion in cost-reduction costs, and $633 million in acquired IPR&D. Revenue was held flat by foreign exchange (+$1.6 billion) and strong patent-protected products such as Lyrica (+41%), Sutent (+46%), and Xalatan, which offset the loss of U.S. exclusivity on Norvasc, Camptosar, and Zyrtec, and the weakening of Lipitor (down 2% to $12.4 billion, with U.S. sales down 12%). The defining event is the pending $68 billion cash-and-stock acquisition of Wyeth, announced January 26, 2009, at $50.19 per share ($33 cash plus 0.985 Pfizer shares per Wyeth share). Pfizer plans to fund it with about $22.5 billion of cash, $22.5 billion of new acquisition debt, and about $23 billion of stock, and expects closing in late Q3 or Q4 2009. The filing signals meaningful balance-sheet and shareholder-return changes: Moody's and S&P have placed Pfizer on review for downgrade, the quarterly dividend will be cut from $0.32 to $0.16 starting Q2 2009, and buybacks are capped at $500 million pending closing. Management also announced a new cost-reduction program targeting about $3 billion in adjusted cost savings by 2011 (net $2 billion after reinvestment), with a roughly 10% workforce reduction and about $6 billion in related pre-tax costs. For investors, the 2009 guidance of reported diluted EPS of $1.34 to $1.49 and Adjusted EPS of $1.85 to $1.95 reflects purchase-accounting drag and restructuring costs. The key debates are the pace of the Lipitor and Norvasc erosion, the value of the Wyeth combination and its accretion timeline (expected in 2011), the scale of ongoing litigation, and the dividend reset and leverage increase that accompany the deal.
Feb 27, 2009
2007
PFIZER INC Annual Report, Year Ended Dec 31, 2007
Pfizer's 2007 Form 10-K shows a company whose revenue was flat at $48.4 billion, but whose profitability fell sharply. Reported net income dropped 58% to $8.1 billion from $19.3 billion in 2006, which was inflated by the one-time $7.9 billion after-tax gain on the Consumer Healthcare sale. Diluted EPS was $1.17 versus $2.66. Management's Adjusted income, which excludes purchase accounting, acquisition costs, discontinued operations and certain significant items, rose about 1% to $15.1 billion (Adjusted diluted EPS $2.18). The main drags were a $2.8 billion pre-tax charge to exit the inhaled insulin product Exubera and roughly $3.9 billion of cost-reduction spending, which is part of a plan to eliminate about 10,000 positions by the end of 2008. Revenue quality is under pressure. Pharmaceutical sales fell 1% to $44.4 billion as loss of U.S. exclusivity hit Norvasc (down 38%) and Zoloft (down 75%). Lipitor, the largest product at $12.7 billion, declined 2% and is facing generic statin competition, a 2010-2011 U.S. patent cliff, and a patent reexamination. Newer launches such as Lyrica, Chantix and Sutent offset some of the decline. Management's 2008 guidance calls for revenue of $47.0-49.0 billion, reported diluted EPS of $1.78-1.93 and Adjusted diluted EPS of $2.35-2.45, implying a further year of pressure. Moody's has moved Pfizer's Aa1 outlook to negative. The balance sheet remains strong, with $26.1 billion in cash and short-term investments and a current ratio of 2.15:1. Total debt rose to $13.1 billion, and the company returned $10.0 billion through buybacks and $8.0 billion in dividends. The dividend was raised to $1.16 per share, the 41st consecutive annual increase. Investors should weigh that capital return against the patent-expiry risk and the large restructuring program still in progress.
Feb 29, 2008
2006
PFIZER INC Annual Report, Year Ended Dec 31, 2006
Pfizer's 2006 Form 10-K shows a company in transition. Revenues rose 2% to $48.4 billion, but the growth was driven by a broad portfolio of patent-protected drugs and new launches, offset by loss of U.S. exclusivity on Zithromax (November 2005) and Zoloft (June 2006), which together fell about $2.5 billion. Reported net income surged to $19.3 billion from $8.1 billion, but that jump is mainly the $7.9 billion after-tax gain on the December 2006 sale of the Consumer Healthcare business to Johnson & Johnson for $16.6 billion, plus a lower effective tax rate of 15.3% (versus 29.4% in 2005, which carried a $1.7 billion repatriation charge). Income from continuing operations rose to $11.0 billion, and the company's Adjusted income, a non-GAAP measure management uses internally, was roughly flat at $15.0 billion versus $14.5 billion. The forward outlook is more cautious. Management expects 2007 and 2008 revenues to be broadly comparable to 2006, with patent expirations on Norvasc and Zyrtec (2007) and Camptosar (2008) offsetting new product growth. Pfizer announced a plan to eliminate about 10,000 positions (roughly 10% of the workforce) by end-2008 and to cut pre-tax expenses by $1.5 to $2.0 billion versus 2006 under its expanded Adapting to Scale program, and it plans to repurchase up to $10 billion of stock in 2007. Lipitor, at about $12.9 billion (28.6% of Pharmaceutical revenue), remains a major concentration risk as generic statins launched in 2006 and the primary U.S. patent expires in 2010. Balance sheet and risk items to note: net financial assets rose to $24.1 billion from $7.3 billion after the divestiture, and total debt fell to $8.0 billion from $17.9 billion. Moody's cut Pfizer's long-term rating to Aa1 in December 2006 after the torcetrapib program was discontinued, and S&P moved its outlook to negative. The company also faces extensive product liability, patent, and government investigation matters, including Celebrex/Bextra litigation, Neurontin and Lipitor marketing suits, and a securities class action tied to torcetrapib.
Mar 1, 2007
2005
PFIZER INC Annual Report, Year Ended Dec 31, 2005
Pfizer's 2005 10-K shows a company under heavy revenue pressure but still highly profitable. Total revenues fell 2% to $51.3 billion, while net income dropped 29% to $8.1 billion from $11.4 billion. The decline was driven by loss of U.S. exclusivity on key products (Neurontin, Diflucan, Accupril, and Zithromax), the suspension of Bextra sales, and uncertainty around Celebrex. Those factors cut revenues by about $5.7 billion versus 2004. Reported earnings were also hit by $1.7 billion of acquired in-process R&D (mainly Vicuron and Idun), $1.2 billion of Bextra-related impairments and charges, and $1.7 billion of tax on repatriating roughly $37 billion of foreign earnings. Adjusted income, a non-GAAP measure management uses, fell 7% to $15.0 billion. Management is leaning on its cost program and pipeline to offset the revenue loss. The Adapting to Scale initiative is targeted to deliver about $4 billion in annual savings by 2008, with roughly $800 million already achieved in 2005. Several launches (Lyrica, Exubera, Sutent, Eraxis) and the Lipitor franchise are expected to drive 2006 revenues, which management expects to be roughly flat with 2005. Guidance calls for reported net income of about $11.4 to $11.7 billion and diluted EPS of $1.52 to $1.56. That guidance excludes the purchase-accounting effects of a pending business-development deal and any impact from exploring strategic options for Consumer Healthcare, which may be sold or spun off with a decision expected in Q3 2006. The balance sheet remains strong, with $22.7 billion in cash and short-term investments, $17.9 billion in total debt, and shareholders' equity of $65.6 billion. Pfizer holds AAA/Aaa ratings, though Moody's has a negative outlook. Key risks include the 2006 patent expiry of Zoloft, the 2007 expiries of Norvasc and Zyrtec, Lipitor generic competition beginning in 2006 (with U.S. patent litigation on appeal), Medicare Part D and Medicaid pricing pressure, and extensive product liability and securities litigation, including Celebrex, Bextra, Neurontin, and Viagra matters.
Mar 1, 2006
2004
PFIZER INC Annual Report, Year Ended Dec 31, 2004
Pfizer's 2004 Form 10-K (filed February 28, 2005) describes a year dominated by the Pharmacia acquisition, which lifted revenues 17% to $52.5 billion and net income to $11.4 billion from $3.9 billion in 2003. The 2003 comparison is distorted by roughly $5.1 billion of in-process R&D charges and $2.7 billion of inventory step-up charges, so reported earnings growth overstates underlying momentum. Adjusted Income, a non-GAAP measure management uses internally, rose 31% to $16.1 billion. Human Health generated 88% of revenue, and ten products each exceeded $1 billion, with Lipitor becoming the industry's first $10 billion product. The filing is equally clear about risks. Celebrex and Bextra face regulatory reviews by the FDA and EMEA over cardiovascular safety following Merck's Vioxx withdrawal, and management warns that a significant loss of sales of either would materially hurt results. Several major franchises face generic erosion: Neurontin and Diflucan were hit in late 2004, Zithromax retains U.S. patent protection only until November 2005, and Zoloft and Norvasc lose U.S. exclusivity in 2006 and 2007. Pfizer also disclosed a $369 million asbestos charge tied to Quigley, a $691 million Depo-Provera impairment, and numerous pending product liability and securities suits. Capital returns remain a central part of the story. Pfizer repurchased $6.7 billion of stock in 2004, paid $5.1 billion in dividends, and raised the annual dividend to $0.68 from $0.60, and it launched a new $5 billion buyback expected to be completed by the end of 2005. Management expects Pharmacia cost synergies of about $4.2 billion in 2005 and says the company may repatriate up to $29 billion under the American Jobs Creation Act, though the tax effect cannot yet be estimated. Investors will want to watch whether synergy gains and new launches can offset the patent cliff ahead.
Feb 28, 2005
2003
PFIZER INC Annual Report, Year Ended Dec 31, 2003
Pfizer's 2003 10-K reflects a transformational year, dominated by the April 2003 acquisition of Pharmacia in a roughly $56 billion stock-for-stock deal that made Pfizer the world's largest pharmaceutical company. Revenues rose 40% to $45.2 billion, with Pharmaceutical sales up 40% to $39.6 billion (88% of the total), Consumer Healthcare up 20% to $3.0 billion, and Animal Health up 43% to $1.6 billion. Much of the top-line growth reflects the inclusion of legacy Pharmacia products, a weaker U.S. dollar, and strong performances from Lipitor, Norvasc, Zoloft, Neurontin and Zithromax, each of which exceeded $2 billion or $1 billion in sales. Reported profitability fell sharply. Net income dropped 57% to $3.9 billion (EPS of $0.54 diluted) from $9.1 billion in 2002, driven by non-cash purchase accounting charges of roughly $10.2 billion pre-tax, including a $5.1 billion in-process R&D write-off and a $2.8 billion inventory step-up, along with a $1.4 billion legal provision tied to Rezulin and Neurontin matters and a 49.7% effective tax rate. Management's adjusted income, which excludes these items, rose 28% to $12.7 billion. The company also divested Adams confectionery, Schick-Wilkinson Sword and women's health lines for a combined gain of roughly $2.3 billion after tax, and guided to 2004 revenue of about $54 billion and adjusted diluted EPS of $2.13. Investors should weigh the strong franchise and synergy outlook (about $3.4 billion of cumulative Pharmacia cost synergies expected in 2004) against heavy exposure to patent expirations and generic competition, including Diflucan's U.S. basic patent expiry in January 2004, with Lipitor, Norvasc, Neurontin and Celebrex all facing legal challenges. Balance sheet strength remains intact with AAA/Aaa long-term ratings, though total debt rose to $14.6 billion and goodwill and intangibles now total about $58 billion, creating future impairment and amortization risk (roughly $3.4 billion of annual amortization expected in 2004).
Mar 10, 2004
2002
PFIZER INC Annual Report, Year Ended Dec 31, 2002
Pfizer's 2002 Form 10-K shows a company at peak scale: total revenues grew 12% to $32.4 billion, net income rose 17% to $9.1 billion, and diluted EPS grew 20% to $1.46. Growth was driven by the human pharmaceutical franchise (revenues up 12% to $28.3 billion), with ten products each exceeding $1 billion in annual sales, including Lipitor, the world's largest-selling prescription drug. Results were also affected by non-cash charges (a $410 million after-tax goodwill impairment on adopting SFAS 142) and Warner-Lambert merger integration and restructuring costs of $331 million after tax. Management forecasts 2003 diluted EPS of about $1.80 excluding significant items and merger costs on a stand-alone basis, and does not forecast reported EPS because of the pending Pharmacia acquisition and divestitures. The filing is dominated by two pending transactions. The roughly $60 billion all-stock Pharmacia acquisition (about 2 billion Pfizer shares to be issued) was cleared by shareholders and the European Commission and was expected to close in April 2003 after an FTC consent decree. Pfizer is also divesting non-core businesses: the Adams confectionery unit ($4.2 billion), Schick-Wilkinson Sword ($930 million), and certain women's health lines ($359 million plus up to $125 million contingent). These sales are expected to close in the first half of 2003 and would reshape the company's consumer exposure. Key risks for investors include patent expirations and generic competition (Accupril, Diflucan, Zithromax and Zoloft face expiry between 2003 and 2006), pricing pressure from managed care and proposed Medicare/Medicaid reforms, pending patent litigation on Lipitor, Norvasc, Neurontin and Celebrex, a large Rezulin product liability docket (about 8,700 suits), a federal investigation of Neurontin promotion, and roughly 128,000 asbestos claims tied to Quigley and American Optical. Balance sheet strength remains high, with Aaa/AAA long-term debt ratings, $12.95 billion in cash and short-term investments, and $5 billion in share buybacks during 2002.
Mar 27, 2003
2001
PFIZER INC Annual Report, Year Ended Dec 31, 2001
Pfizer's 2001 10-K (filed March 2002) shows a company whose reported results were driven by the Warner-Lambert merger's aftermath and a strong core pharmaceutical franchise. Total revenues grew 10% to $32.3 billion, with human pharmaceuticals up 13% to $25.5 billion and eight products each exceeding $1 billion in sales (Lipitor, Norvasc, Zoloft, Neurontin, Viagra, Zithromax, Celebrex and Diflucan). Net income more than doubled (up 109%) to $7.8 billion, and diluted EPS rose 107% to $1.22. Investors should note that these headline gains are flattered by merger-related dynamics: the prior year carried $3.3 billion of merger costs, and 2001 includes a one-time $175 million Medicaid accrual harmonization benefit. Excluding certain significant items and merger-related costs, diluted EPS grew 28% to $1.31, which is the more representative measure of operating momentum. The filing highlights several risks. Foreign exchange was a significant headwind, reducing revenues by $861 million. Lipitor and Norvasc face looming patent and pricing pressures in the U.S., and the company disclosed that patents on Neurontin, Diflucan and Zoloft are under legal challenge from generic manufacturers. Management also flagged U.S. pricing pressure from Medicare reform debates, managed care consolidation, and growing generic competition. Litigation exposure is substantial, including over 2,000 Rezulin suits, about 168,000 asbestos claims, and government investigations into Neurontin and Lipitor marketing and pricing practices. Management maintains that these matters should not have a material adverse effect on financial condition. Looking forward, management guided to double-digit annual revenue growth through 2004 at current exchange rates, 2002 diluted EPS of $1.56 to $1.60 excluding significant items, and average annual EPS growth of 15% or better for 2003 and 2004. R&D spending was projected to rise about 10% to $5.3 billion, and merger-related cost savings were expected to reach $1.7 billion by the end of 2002. The balance sheet remained strong, with AAA/Aaa credit ratings, $8.9 billion in cash and short-term investments, and a dividend that marked its 35th consecutive year of increases.
Mar 28, 2002
1999
PFIZER INC Annual Report, Year Ended Dec 31, 1999
Pfizer's 1999 10-K shows a strong operating year overshadowed by a pending transformational deal. Total revenues grew 20% to $16.2 billion, driven by 19.6% volume growth, with Pharmaceuticals up 22% to $14.9 billion. Growth was led by in-line blockbusters (Norvasc, Zoloft, Zithromax, Viagra, Diflucan) and alliance revenue, which rose to $2.1 billion from $867 million, reflecting Lipitor, Aricept and Celebrex. Reported net income fell 5% to $3.18 billion, but this reflects a $310 million Trovan inventory write-off and the absence of roughly $883 million in 1998 one-time charges; excluding these items, net income rose about 29% and diluted EPS rose 30% to $0.87. Diluted EPS as reported was $0.82. The central investor event is the February 2000 agreement to merge with Warner-Lambert in a pooling-of-interests transaction valued at about $90 billion, expected to close in mid-2000. Management projects 13% revenue CAGR and 25% earnings growth through 2002, $1.6 billion in annual cost savings by 2002, and pro forma diluted EPS of $0.98 in 2000 rising to $1.56 in 2002, before $1.7 to $2.2 billion in restructuring and transaction costs. Investors should weigh that upside against integration risk and against the dependence of the standalone franchise on a few products. The balance sheet remains solid but has become more leveraged. Short-term borrowings rose to $5.0 billion, used largely to fund $2.5 billion of share repurchases, and net financial assets fell to $910 million from $2.6 billion. Cash and short-term investments of $4.7 billion and Aaa/AAA debt ratings provide substantial liquidity. Key risks include generic erosion of Procardia XL (sales down to $521 million from $822 million in 1997), the expiry of the Cardura patent in 2000, Medicare drug-pricing debates, and several pending patent and product-liability suits, including Trovan litigation with a $143 million jury verdict.
Mar 27, 2000
1998
PFIZER INC Annual Report, Year Ended Dec 31, 1998
Pfizer's 1998 results were a step-change year, driven by volume growth in its core pharmaceutical franchise and a large one-time gain from exiting the medical device business. Total revenues rose 23% to $13.5 billion, with pharmaceutical revenues up 26% to $12.2 billion. Volume was the dominant driver (+24.8%), while currency reduced revenues by roughly 3.5%. Growth was led by Viagra (launched 1998, $788 million in sales), Zithromax (+27%), Zoloft (+22%), Norvasc (+16%, now the largest-selling product at $2.6 billion), and Zyrtec (+57%). Net income rose 51% to $3.35 billion, but this figure is inflated by $1.4 billion of discontinued-operations income from the sale of the Medical Technology Group (Schneider, Howmedica, Valleylab, American Medical Systems). Income from continuing operations actually fell 6% to $1.95 billion, reflecting roughly $1.0 billion of 'other deductions,' including a $300 million contribution to The Pfizer Foundation, $240 million in copromotion payments to Searle for Celebrex, $213 million of asset impairments, and $177 million of restructuring charges. Diluted EPS was $2.55 reported, but only about $2.00 excluding significant charges. The key investor watch items are concentration and patent exposure. Norvasc, Zithromax and Zoloft together account for about 40% of revenue, and several major U.S. patents expire between 2000 and 2011. Procardia XL is in decline ($714 million, down 13%) and faces generic challengers, with active litigation over the patent. Pressure from managed care, Medicaid rebates, and possible Medicare reform is expected to continue. Financially, the balance sheet strengthened: net financial assets rose to $2.6 billion from essentially zero, and operating cash flow reached $2.9 billion. The company also committed to a $5 billion buyback program and announced a three-for-one stock split for April 1999, with the dividend raised 16% to $0.22 per quarter.
Mar 26, 1999
1996
PFIZER INC Annual Report, Year Ended Dec 31, 1996
Pfizer's 1996 Form 10-K shows a strong year driven by volume growth in its core pharmaceutical franchise. Net sales rose 13% to $11.3 billion, net income increased 23% to $1.93 billion, and EPS grew 20% to $2.99. The Health Care segment generated 85% of revenue ($9.6 billion, up 15%), with pharmaceuticals at $8.2 billion (up 16%). Three products (Norvasc, Zoloft and Procardia XL) each exceeded $1 billion in sales, and the company describes a pipeline of 13 new chemical entities in late-stage development or regulatory review. Gross margin improved as cost of sales fell to 19.3% of sales from 21.6%, and the effective tax rate dropped to 31.0% from 32.1%. The filing also highlights meaningful risks. Pfizer relies heavily on a small number of products, and Procardia XL faces future competition from other sustained-release nifedipine products, with its patent protected until 2003. Feldene and Glucotrol have already lost U.S. exclusivity to generics. Managed care pressure, Medicaid rebate obligations and possible U.S. health care reform are flagged as pricing headwinds for 1997. The company also discloses extensive litigation, including Shiley heart valve claims, pharmacy antitrust suits, asbestos claims, and a Brazilian civil action with a potential payment of about $88 million, though management consistently states these should not have a material adverse effect. Financial strength remained solid. Operating cash flow reached $2.07 billion, and debt to total capitalization fell to 30% from 34%. Senior debt carried Aaa/AAA ratings for the 11th consecutive year. Management plans to raise 1997 R&D spending to about $2.0 billion, and the board has proposed a two-for-one stock split, subject to shareholder approval of more authorized shares at the April 1997 annual meeting.
Mar 28, 1997
1995
PFIZER INC Annual Report, Year Ended Dec 31, 1995
Pfizer's 1995 fiscal year was a landmark year: net sales from continuing operations crossed $10.0 billion for the first time (up 26% from $7.98 billion in 1994), and net income rose 21% to $1,572.9 million, or $2.50 per share. Growth was driven overwhelmingly by volume (24 points of the 26% increase), with essentially no contribution from pricing (-1 point). The Health Care segment, which generated 84% of sales ($8.41 billion, up 21%), remained the core of the business, led by a portfolio of 1990s launches: Norvasc (about $1.3 billion), Procardia XL (about $1.1 billion), Zoloft (about $1.0 billion), and Diflucan (about $880 million). The $1.5 billion acquisition of SmithKline Beecham's animal health business in January 1995 lifted Animal Health sales 101% to $1.22 billion, and the purchase also added goodwill amortization and interest costs that pushed Other deductions-net up 128%. Margins held up: the effective tax rate rose to 32.1% from 30.0%, while SI&A fell to 38.5% of sales from 39.9%, reflecting cost discipline. Liquidity remained solid, with operating cash flow of $1.82 billion, Aaa/AAA debt ratings, and shareholders' equity per share up to $8.90 from $7.10. Investors should weigh several risks. The U.S. pricing environment is tightening through managed care growth, Medicaid rebates ($85 million in 1995), and price competition. Procardia XL faces future competition from sustained-release nifedipine generics, and the FDA advisory panel's January 1996 review of calcium channel blockers created label uncertainty for immediate-release nifedipine (Procardia). Pending U.S. legislation could phase out the Section 936 Puerto Rico tax credit, and an IRS dispute over 1987-1989 swap transactions (about $72 million plus interest, with a potential additional $86 million) and Belgian tax assessments of roughly $432 million plus interest are unresolved. Pfizer maintains that none of these matters should have a material adverse effect. Litigation exposure includes Shiley heart valve claims, asbestos cases, a federal retail pharmacy antitrust class action (the Company's share of the settlement is $31.25 million), and a Brazilian judgment with a potential $88 million public fund payment. Looking ahead, management planned to spend about $1.7 billion on R&D in 1996, up from $1.44 billion in 1995, and it disclosed 15 new chemical entities in late-stage development. Pending FDA filings include Zithromax indications, Zoloft for panic disorder, and tenidap for arthritis. Recent deals include the Leibinger acquisition in January 1996 and the Cortizone/Hemorid brand purchase, while the food science business was divested to Cultor for about $350 million. The company also raised its quarterly dividend 15% to $0.30 in January 1996, extending its streak of consecutive annual dividend increases to 29 years.
Mar 29, 1996
1994
PFIZER INC Annual Report, Year Ended Dec 31, 1994
Pfizer's 1994 Form 10-K shows a company in strong operating recovery after a difficult 1993. Net sales rose 11% to $8.28 billion, and net income more than doubled to $1.30 billion ($4.19 per share) from $657.5 million ($2.05 per share) in 1993. The 1993 figure carried a $750 million restructuring charge, so on an ongoing basis net income grew about 10% and EPS about 13%. Growth was driven almost entirely by volume from newer pharmaceuticals. Pharmaceuticals reached 70% of sales, and the six launched-in-the-1990s products (Norvasc, Diflucan, Zoloft, Cardura, Zithromax, Glucotrol XL) grew 44% and represented 33% of sales. Research and development spending rose 17% to $1.14 billion, with about $1.4 billion planned for 1995, which signals continued investment in the pipeline. The balance sheet and cash flow picture is more mixed. Operating cash flow was a solid $1.49 billion, but debt-to-total-capitalization rose to 40% from 31%, largely from share repurchases and increased short-term borrowings. Short-term borrowings reached $2.2 billion. Early 1995 brought significant transactions: the roughly $1.45 billion acquisition of SmithKline Beecham's animal health business, a planned $175 million NAMIC acquisition, and a proposed two-for-one stock split. Pfizer also reported a dividend increase of 11% for 1995, its 28th consecutive annual increase, and maintained Aaa/AAA credit ratings. Key risks flagged in the filing include exposure to generic competition as Feldene and Glucotrol mature, pressure on U.S. pricing from managed care and rebate legislation, uncertainty around health care reform, and significant litigation. The most prominent litigation involves Shiley C/C heart valves, along with asbestos, antitrust suits from retail pharmacies, and penile prosthesis class actions. Management states that none of these is expected to have a material adverse effect, though the Shiley and product liability matters remain the main sources of uncertainty.
Mar 24, 1995
1993
PFIZER INC Annual Report, Year Ended Dec 31, 1993
Pfizer's 1993 Form 10-K shows a company in transition. Reported net sales rose 3% to $7.48 billion, but reported net income fell 19% to $657.5 million ($2.05 per share), down from $810.9 million ($2.41) in 1992. The decline was driven by a $750 million pre-tax ($525 million after-tax) restructuring and unusual-items charge taken in the third quarter of 1993, which is designed to cut at least $130 million in annual operating costs and reduce the workforce by about 3,000 employees. Excluding divestitures, restructuring, and unusual items, Pfizer's net income would have been $1,183.9 million ($3.70 per share), up 15% from ongoing 1992 results, and ongoing net sales grew 9%. Growth was concentrated in pharmaceuticals, which reached 69% of consolidated sales, led by Norvasc, Zoloft, Zithromax, Diflucan, and Procardia XL. Investors should weigh several risks. Health care reform proposals, including the Administration's Health Security Act, could pressure U.S. drug pricing, and near-term generic competition is expected for Feldene and Glucotrol. Pfizer also faces significant product liability exposure from Shiley C/C heart valve litigation, although management believes it is covered largely by insurance and reserves. The tax picture is also changing: the 1993 Omnibus Budget Reconciliation Act reduces the Puerto Rico tax credit benefit and is expected to raise the effective tax rate from 26% to about 30% in 1994. Balance sheet strength remains a positive, with Aaa/AAA senior debt ratings, $1.2 billion of cash and short-term investments, and $1.2 billion of unused credit lines. Debt to total capitalization rose to 31% after share repurchases and the $600 million Employee Benefit Trust transaction. On the outlook side, management plans to spend more than $1.1 billion on R&D in 1994, and it has said the U.S. pharmaceutical price increase will be under 2.5% for 1994. The company's 1994 dividend was $0.47 per share, payable in the first quarter.
Mar 25, 1994